the recommendations of the sub-committee for weeding out certain combination of drugs, a statement about which is annexed. (*See* below)

Government is taking steps to notify for prohibiting marketing of the drugs falling under these categories in consultation with Ministry of Law.

Statement

1. Fixed dose combination of tranquillizers with analgesics—antipyretics.

2. Fixed dose combination of Pyrazinamide and other anti-T.B. drugs.

3. Fixed dose combination of anti-ulcer (H2 receptor antagonist, such as cimetidine, Ranitidine, etc.) with other drugs.

4. Fixed dose combination of essential oils with alcohol with percentage higher than 20 per cent proof.

5. Fixed dose combination of chloroform with other drugs.

Non inclusion of ferrous sulphate tablets under price control order

146. SHRI DAYANAND SAHAY: Will the Minister of HEALTH AND FAMILY WELFARE be pleased to refer to answer to Unstared Question 3506 given in the Rajya Sabha on the 9th December, 1987 and state:

(a) whether it is a fact that Ferrous Sulphate Tablets are used under Maternal and Child Health Programme;

(b) whether it is also a fact that Ferrous Sulphate is not imported and country is self sufficient;

(c) whether it is also a fact that as per the policy decision, the Ministry of Health and Family Welfare is to recommend of drugs used for Health Programme for price control;

(d) whether the prices of Ferous Sulphate Tablets, such as Fersolate Tablets, have gone up by 100 per cent; and

(e) what are the reasons for recommending which the Ministry of Health and Family Welfare for price control Ferrous Sulphate and allowed the consumer to be overcharged when 80 per cent of the population is suffering from anaemic deficiency and 60 per cent of pregnant women?

THE MINISTER OF HEALTH AND FAMILY WELFARE (SHRI MOTI LAL VORA): (a) Yes, Sir.

(b) The production and availability of drugs is controlled by Department of Chemicals, Minisry of Industry.

(c) Yes, Sir.

(d) The pricing is monitored by the Department of Chemicals.

(e) Ferrous Sulphate has not been recommended as yet for price control.

Essential drugs

147. DR. (SMT.) SAROJINI MAHISHI: Will the Minister of HEALTH AND FAMILY WELFARE be pleased to state:

(a) whether his Ministry has compiled a list of essential drugs;

(b) if so, what are the names of those drugs, alongwith the indication for which each is used;

(c) whether it is also a fact that the list was compiled by a committee; and

(d) if so, what are the names of the members, alongwith designation and organisation which each one of them represent?

THE MINISTER OF HEALTH AND FAMILY WELFARE (SHRI MOTI LAL VORA): (a) and (b) Ministry

of Health and Family Welfare is engaged in updating list of drugs which are considered essential at various levels of health care such as Primary Health Centre and Community Health Centre. This exercise, however, is not yet complete.

(c) and (d) The lists are being compiled by a Committee of members representing Directorate General of Health Services, Ministry of Health and Family Welfare and State Officials. The names of members who participated in updating the list is enclosed.

List of Participants

1. Dr. A. K. Mukherjee—*Chairman* Additional D. G. (PH), Directorate General of Health Services.
2. Dr. J. L. Kole, DDG (RH) Directorate General of Health Services.
3. Dr. G. V. Satyavati, Sr. Dy. Director General, I.C.M.R., New Delhi.
4. Dr. Daya Sharma, Prof. of Paediatrics LHMC., New Delhi.
5. Dr. Snehlata Mishra, Prof. of Obstetrics & Gynae, Lady Harding Medical College, New Delhi.
6. Dr. T. K. Mullick, Prof. of Surgery, Maulana Azad Medical College, Delhi.
7. Dr. R. C. Bhasin, Prof. of Medicine, Dr. Ram Manohar Lohia Hospital, New Delhi.
8. Dr. P. N. Ghei, Deputy Commissioner (PA), Ministry of Health and Family Welfare, New Delhi.
9. Dr. P. Das Gupta, Deputy Drug Controller, Directorate General of of Health Services, New Delhi.
10. DR. R. K. Mishra, Deputy Director of Health Services, Madhya Pradesh, Bhopal.
11. Dr. M. C. Verma, Joint Director, Uttar Pradesh, Lucknow.
12. Dr. S. S. Upadhyay, Research Officer, Lucknow.
13. Dr. S. C. Sharma, Asstt. Director General (HA), Directorate General of Health Services, New Delhi.
14. Dr. (Ms.) A. Bhardwaj, Assistant Commissioner (Trg.), Directorate General of Health Services. New Delhi.
15. Dr. (Mrs.) T. Bhasin, Assistant Commissioner (RHS), Directorate General of Health Services, New Delhi.
16. Dr. V. N. Sardana, Dy. Assistant Directorate General (CH), Directorate General of Health Services, New Delhi.
17. Dr. (Mrs.) K. Kehar, Chief Medical Officer, Directorate General of Health Services, New Delhi.
18. Mr. T. Dileep Kumar, Dy. Nursing Adviser, Directorate General of Health Services, New Delhi.

Marketing of Drugs for leprosy, TB and Diarrhoea

148. DR. BAPU KALDATE: Will the Minister of HEALTH AND FAMILY WELFARE be pleased to state:

(a) what are the names of drugs which have been allowed for marketing for treatment of leprosy, TB and Diarrhoea in the country by the Drugs Control Administation;

(b) whether Government have allowed any combination of drugs for treatment of diseases;

(c) if so, what are the details of composition of each;

(d) whether it is a fact that Ministry of Health and Family Welfare is representing the recommendatory committee for price fixation of these medicines;